- Conditions
- Breast Cancer
- Interventions
- Ribociclib
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 132
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Placebo
- Drug · Other
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 3,966 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2025
- U.S. locations
- 777
- States / cities
- Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 523 more
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
- Interventions
- Neratinib, Letrozole (L) or Anastrozole (A), Trastuzumab
- Drug
- Lead sponsor
- Ruth O'Regan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Rochester, New York • Hershey, Pennsylvania + 1 more
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions
- Palbociclib + Letrozole or Fulvestrant
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more
- Conditions
- Polycystic Ovary Syndrome, Infertility
- Interventions
- Clomiphene, Letrozole
- Drug
- Lead sponsor
- Rachel Mejia
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
- Interventions
- Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo
- Drug
- Lead sponsor
- Olema Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 62
- States / cities
- Hot Springs, Arkansas • Beverly Hills, California • La Jolla, California + 54 more
- Conditions
- Breast Cancer
- Interventions
- BMS-690514, Lapatinib, Letrozole
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 4
- States / cities
- Abilene, Texas • Beaumont, Texas • Fort Worth, Texas + 1 more
- Conditions
- Breast Cancer
- Interventions
- Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Anastrozole, Letrozole, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 20
- States / cities
- Chandler, Arizona • Springdale, Arkansas • Bakersfield, California + 13 more
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Anastrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 33 Years to 96 Years · Female only
- Enrollment
- 4,172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Flagstaff, Arizona + 35 more
- Conditions
- Breast Cancer Female
- Interventions
- Letrozole
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
- Interventions
- letrozole, lapatinib, everolimus
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer
- Interventions
- Ribociclib, Adjuvant endocrine therapy, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Letrozole, Trastuzumab
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • St Louis, Missouri + 1 more
- Conditions
- Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Interventions
- Ribociclib, Fulvestrant, Anastrozole, Letrozole, Exemestane
- Drug
- Lead sponsor
- Oana Danciu
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 18 more
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 74 more
- Conditions
- Breast Cancer
- Interventions
- MK-0752
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Breast Cancer
- Interventions
- letrozole
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Breast Cancer
- Interventions
- Ribociclib, Letrozole, Goserelin, Leuprolide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 71
- States / cities
- Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
- Conditions
- Breast Neoplasms
- Interventions
- Letrozole, Afatinib
- Drug
- Lead sponsor
- Translational Research in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 9
- States / cities
- Fullerton, California • Los Angeles, California • Northridge, California + 6 more
- Conditions
- Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Interventions
- Giredestrant, Giredestrant-matched Placebo, Letrozole, Letrozole-matched Placebo, Palbociclib, LHRH Agonist
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 37
- States / cities
- Fountain Valley, California • Long Beach, California • San Leandro, California + 32 more
- Conditions
- Breast Cancer
- Interventions
- Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 176
- States / cities
- Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 139 more
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 29
- States / cities
- Berkeley, California • Duarte, California • Irvine, California + 22 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Dasatinib, Letrozole
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 27
- States / cities
- Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more